Lipoprotein lipase Inhibitors
3 drugsAbout Lipoprotein lipase
Lipoprotein lipase (LPL) hydrolyzes triglycerides in lipoproteins, releasing fatty acids for tissue uptake and energy storage. This enzyme plays a crucial role in lipid metabolism by processing fats in the body.
LPL is a therapeutic target for modulating triglyceride levels, particularly in metabolic disorders. Currently, there is no genetic evidence available linking LPL to specific diseases.
LPL is targeted by 3 FDA-approved small molecule drugs, including VASCEPA, LOVAZA, and OMEGA-3-ACID ETHYL ESTERS. These drugs are developed by Apotex, AMARIN PHARMS, and WAYLIS THERAP.
Top Lipoprotein lipase Drugs
The competitive landscape consists of 3 companies with approved drugs.
Low market concentration suggests opportunities for new entrants, but established players pose a threat.
Lipoprotein lipase Drug Modality Landscape
Modalities
Routes of Administration
Lipoprotein lipase is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or gene therapies could provide a competitive advantage.
Lipoprotein lipase Clinical Trials 64 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Lipoprotein lipase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 20 | 7 | 13 | 0 | 35% |
| Phase 2 | 16 | 10 | 3 | 3 | 77% |
| Phase 3 | 14 | 8 | 3 | 3 | 73% |
| Phase 4 | 14 | 9 | 4 | 1 | 69% |
Top Sponsors
By Modality
Top Conditions
Lipoprotein lipase Drug Approval Timeline (2004 - 2012)
The first drug targeting LPL was approved in 2004, and the most recent in 2014.
The approval timeline indicates a potentially saturated market, requiring differentiated products for success.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 42 (7 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Lipoprotein lipase. A trial counts if an approved drug acting on Lipoprotein lipase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.